In 2025, European MedTech companies are facing a more selective funding environment, where capital is still available but increasingly allocated to businesses able to demonstrate clear clinical, regulatory, and commercial proof within shorter timeframes, putting pressure on already long and capital-intensive development cycles. This tightening has led to slower growth, increased consolidation, and, in some cases, liquidity crises, making support from specialized advisors like RightLiens—an independent, healthcare-focused investment bank staffed by former executives—particularly critical.